Cite
MLA Citation
A Deodhar et al.. “THU0359 Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials.” Annals of the rheumatic diseases, vol. 76, n.d., pp. 340–341. http://access.bl.uk/ark:/81055/vdc_100135163390.0x000062